Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

The NASH drugs in development market research report provides comprehensive information on the therapeutics under development for the NASH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for NASH and features dormant and discontinued projects.

Key Targets in the NASH Pipeline Drugs Market

Key targets in the NASH pipeline drugs market are Glucagon Like Peptide 1 Receptor, Bile Acid Receptor, Glucagon Receptor, Fibroblast Growth Factor Receptor 1, Thyroid Hormone Receptor Beta, and Peroxisome Proliferator Activated Receptor Alpha.

NASH Pipeline Drugs Market, by Targets

NASH Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the NASH Pipeline Drugs Market

Key MoA in the NASH Pipeline Drugs Market are Glucagon Like Peptide 1 Receptor Agonist, Bile Acid Receptor Agonist, Glucagon Receptor Agonist, Thyroid Hormone Receptor Beta Agonist, Glucagon Like Peptide 1 Activator, Fatty Acid Synthase Inhibitor, and Toll Like Receptor 4 Antagonist.

NASH Pipeline Drugs Market, by MoA

NASH Pipeline Drugs Market, by MoA

 To get more insights on key MoA, download a free report sample

Key Molecule Types in the NASH Pipeline Products Market

The different molecule types in the Non-Alcoholic Steatohepatitis (NASH) infections pipeline products market are small molecule, biologic, monoclonal antibody, synthetic peptide, fusion protein, peptide, recombinant protein, and others.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Products Market, by Molecule Type

Non-Alcoholic Steatohepatitis (NASH) Pipeline Products Market, by Molecule Type

To get more insights on key molecule types, download a free report sample

Key Routes of Administration in the NASH Pipeline Products Market

The key routes of administration in the NASH pipeline products market are intramuscular, nasal, oral, parenteral, inhalational, intravenous, subcutaneous, intradermal, and topical.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Products Market, by RoA

Non-Alcoholic Steatohepatitis (NASH) Pipeline Products Market, by RoA

To get more insights on key RoA, download a free report sample

The Major Companies in the Non-Alcoholic Steatohepatitis (NASH) Pipeline Drugs Market

The major companies in the Non-Alcoholic Steatohepatitis (NASH) pipeline products market are AstraZeneca Plc, Novartis AG, Novo Nordisk AS, Ascletis Pharma Inc, Terns Pharmaceuticals Inc, and Yuhan Corp among others.

Non-Alcoholic Steatohepatitis (NASH) Pipeline Drugs Market, by Company

Non-Alcoholic Steatohepatitis (NASH) Pipeline Drugs Market, by Company

For more company insights, download a free report sample

NASH Pipeline Drugs Market Overview

Key target Glucagon Like Peptide 1 Receptor, Bile Acid Receptor, Glucagon Receptor, Fibroblast Growth Factor Receptor 1, Thyroid Hormone Receptor Beta, and Peroxisome Proliferator Activated Receptor Alpha
Key MoA Glucagon Like Peptide 1 Receptor Agonist, Bile Acid Receptor Agonist, Glucagon Receptor Agonist, Thyroid Hormone Receptor Beta Agonist, Glucagon Like Peptide 1 Activator, Fatty Acid Synthase Inhibitor, and Toll Like Receptor 4 Antagonist
Key Molecule Types Small Molecule, Biologic, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Peptide, Recombinant Protein, And Others
Key RoA Intramuscular, Nasal, Oral, Parenteral, Inhalational, Intravenous, Subcutaneous, Intradermal, And Topical
Key Companies AstraZeneca Plc, Novartis AG, Novo Nordisk AS, Ascletis Pharma Inc, Terns Pharmaceuticals Inc, and Yuhan Corp


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH)
  • The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH)
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

180 Life Corp
180 Life Sciences Corp
89bio Inc
AbbVie Inc
Abivax SA
Abliva AB
Ache Laboratorios Farmaceuticos SA
Acquist Theraputics Inc
AdAlta Ltd
Addpharma Inc
Afimmune Biopharma Ltd
Akebia Therapeutics Inc
Akero Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Algernon Pharmaceuticals Inc
Aligos Therapeutics Inc
Allysta Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
Altay Therapeutics Inc
Alteogen Inc
Altimmune Inc
Amgen Inc
Amytrx Therapeutics Inc
Angion Biomedica Corp
Anteris Bio
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd
AptaBio Therapeutics Inc
AptamiR Therapeutics Inc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Holdings Inc
Aria Pharmaceuticals Inc
Arkay Therapeutics LLC
Arrowhead Pharmaceuticals Inc
Artiam Bio Inc
Ascletis Pharma Inc
Asdera LLC
Ashvattha Therapeutics LLC
AstraZeneca Plc
Auransa Inc
Autophagy Science Co Ltd
Avaliv Therapeutics Inc
Avolynt Inc
Axcella Health Inc
Bast Biotechnology LLC
Belite Bio Inc
BenevolentAI Ltd
BerGenBio ASA
Betagenon AB
Bioio LLC
Biotoxtech Co Ltd
Bird Rock Bio Inc
Bisichem Co Ltd
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Brexogen Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
Buto Corp
Cadila Healthcare Ltd
Can-Fite BioPharma Ltd
Cargene Therapeutics Inc
Carmot Therapeutics Inc
Centaurus Therapeutics Inc
Chaser Therapeutics Inc
ChemoCentryx Inc
Chemomab Therapeutics Ltd
Chengdu Fanxi Biopharma Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China NT Pharma Group Co Ltd
Circadian Therapeutics
Cirius Therapeutics Inc
CK Regeon Inc
CohBar Inc
Continuum Biosciences Inc
Corbus Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
Curacle Co Ltd
Curadim Pharma Co Ltd
Curome Bioscience Co Ltd
Cyrus Therapeutics Inc
Cytodyn Inc
D&D Pharmatech Co Ltd
Dr. Falk Pharma GmbH
Eccogene (Shanghai) Co Ltd
Elgia Therapeutics Inc
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Co Ltd
Engitix Ltd
Enspire Bio Inc
Enveda Biosciences Inc
Enyo Pharma SA
Enzychem Lifesciences Corp
Epigen Biosciences Inc
Epitracker Inc
Esperion Therapeutics Inc
Eternygen GmbH
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
Fochon Pharmaceutical Ltd
Forma Therapeutics Inc
Future Medicine Co Ltd
Galectin Therapeutics Inc
Galecto Inc
Galmed Pharmaceuticals Ltd
GAT Therapeutics SL
Genentech USA Inc
General Regeneratives Shanghai Ltd
Genfit SA
GenKyoTex SA
GI Innovation Co Ltd
Gila Therapeutics Inc
Gilead Sciences Inc
Gmax Biopharm LLC
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharma Co Ltd
HemoShear Therapeutics LLC
Hepagene Therapeutics Shanghai Inc
Hepanova Inc
HepaRegeniX GmbH
Hepatx Corp
Hepion Pharmaceuticals Inc
HighTide Therapeutics Inc
Hinova Pharmaceuticals Co Ltd
HK inno.N Corp
HotSpot Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Imago Pharmaceuticals Inc
ImmuneMed Inc
Immupharma Plc
Immuron Ltd
Inipharm Inc
Inmune Bio Inc
Innovimmune Biotherapeutics Inc
Inorbit Therapeutics AB
Intarcia Therapeutics Inc
Integral Molecular Inc
Intercept Pharmaceuticals Inc
INVENT Pharmaceuticals Inc
InventisBio Inc
Inventiva SA
Inversago Pharma Inc
Ionis Pharmaceuticals Inc
J2H Biotech
JD Bioscience Inc
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
Johnson & Johnson
Kine Sciences
Kinomedica Pty Ltd
KoBioLabs Inc
Korea United Pharm Inc
Kowa Co Ltd
Krisani Bio Sciences Pvt Ltd
Kyorin Pharmaceutical Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Landos Biopharma Inc
LegoChem Biosciences Inc
LG Chem Ltd
Life Biosciences LLC
LifeMax Laboratories Inc
Liminal BioSciences Inc
Lipidio Pharmaceuticals Inc
Lipocine Inc
LISCure Biosciences Co Ltd
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
Marvel Biotechnology Inc
Max Biopharma Inc
MD Healthcare Inc
MedPacto Inc
Melior Pharmaceuticals I Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
MetiMedi Pharmaceuticals Co Ltd
Micelle BioPharma Inc
Mikrobiomik Healthcare Company SL
Mina Therapeutics Ltd
Mitotech SA
Mitotherapeutix LLC
Mitsubishi Tanabe Pharma Corp
Mperia Therapeutics Inc
Muen (Guangzhou) Biological Technology Co Ltd
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nano Intelligent Biomedical Engineering Corp
NeuroBo Pharmaceuticals Inc
Nexel Co Ltd
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
NorthSea Therapeutics BV
Novartis AG
Novo Nordisk AS
NovoBiome SAS
NuSirt Biopharma Inc
Oasis Pharmaceuticals LLC
OliX Pharmaceuticals Inc
OncoArendi Therapeutics SA
Onegene Biotechnology Inc
Oramed Pharmaceuticals Inc
Osteoneurogen Inc
Oxitope Pharma BV
Palo BioFarma SL
Panolos Bioscience
Pattern Therapeutics
PegBio Co Ltd
Pfizer Inc
pH Pharma Co Ltd
Pharmaxis Ltd
Phenex Pharmaceuticals AG
Poxel SA
Promethera Biosciences SA
Proterris Inc
Protheragen Inc
PTC Therapeutics Inc
Redx Pharma Plc
Regenasome Pty Ltd
Regulus Therapeutics Inc
Rejuvenation Technologies Inc
Resalis Therapeutics Srl
Revive Therapeutics Ltd
Rhamnopharma Inc
Ridgeline Therapeutics LLC
Rivus Pharmaceuticals Inc
RosVivo Therapeutics Inc
Sagimet Biosciences
Saje Pharma LLC
Salix Pharmaceuticals Ltd
ScandiCure AB
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Seal Rock Therapeutics Inc
Senseion Inc
SFA Therapeutics LLC
Shaanxi Micot Technology Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Anruite Biological Medicine Technology Co Ltd
Shaperon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Tuwei Anchuang Technology Development Co Ltd
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sinew Pharma Inc
Sino Biopharmaceutical Ltd
Sirnaomics Inc
SparkBioPharma Inc
Standigm Inc
SteroTherapeutics LLC
Sumitomo Dainippon Pharma Oncology, Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Sveikatal Inc
Synlogic Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
Tasly Pharmaceutical Group Co Ltd
Terns Pharmaceuticals Inc
TES Pharma SRL
THELMA Therapeutics Co Ltd
Therasid Bioscience
Theratechnologies Inc
Thoth Science Inc
TiumBio Co Ltd
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
TransThera Sciences (Nanjing) Inc
TreeFrog Therapeutics SAS
TSD Life Sciences
Uni-Bio Science Group Ltd
Unicyte AG
Valin Technologies Ltd
Vascular Biogenics Ltd
Vectus Biosystems Ltd
Venenum Biodesign LLC
Venn Therapeutics LLC
VGI Health Technology Ltd
Vidasym Inc
Viking Therapeutics Inc
Viscient Biosciences LLC
Visionary Pharmaceuticals Inc
Vivazome Therapeutics Pty Ltd
Vivoryon Therapeutics NV
Vivus LLC
vTv Therapeutics Inc
Wave Life Sciences Ltd
Xenexus Pharmaceuticals Pty Ltd
Xfibra Inc
Xi'an Xintong Pharmaceutical
Yuhan Corp
Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd
Zhejiang Doer Biologics Corp

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Non-Alcoholic Steatohepatitis (NASH) – Overview

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development

Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects

Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products

Non-Alcoholic Steatohepatitis (NASH) – Product Development Milestones

Featured News & Press Releases




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


Frequently asked questions

Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.